gi-101
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 23, 2021 (NCT04977453)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
- Vaginal Neoplasms · Phase 1/Phase 2
- Vulvar Neoplasms · Phase 1/Phase 2
Mechanism of action
- Cytotoxic T-lymphocyte protein 4ANTAGONIST
CTLA4 antagonist
- Interleukin-2 receptor beta chainBINDING AGENT
IL2RB binding agent
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314985 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04977453 | Phase 1/Phase 2 (Phase 2) | Jul 23, 2021 | GI Innovation, GI Innovation, Inc., Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GI Innovation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| GI Innovation, Inc. | For profit | 1 | 1 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1